Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants
Condition: HIV Infections Interventions: Biological: CH505TF gp120; Biological: GLA-SE adjuvant; Biological: Placebo Sponsors: HIV Vaccine Trials Network; National Institute of Allergy and Infectious Diseases (NIAID) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials